earnings
confidence high
sentiment positive
materiality 0.70
Entrada Q4 net income $1.1M; FDA lifts hold on ENTR-601-44; cash $420M into Q2 2027
Entrada Therapeutics, Inc.
2024-FY EPS reported
$1.68
revenue$210,782,000
- Q4 net income $1.1M vs loss $9.5M YoY; FY net income $65.6M vs loss $6.7M.
- Collaboration revenue $37.4M Q4, $210.8M FY; R&D expenses $33.4M Q4.
- Cash $420M as of Dec 31, 2024; runway expected into Q2 2027.
- FDA lifted clinical hold on ENTR-601-44; authorized US Phase 1b MAD study for exon 44 DMD.
- MHRA authorized UK Phase 1/2 study for ENTR-601-44; regulatory filings for ENTR-601-45 in UK/EU.